Moore RD - Search Results

1

Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea.

Charache S, Terrin ML, Moore RD, Dover GJ, McMahon RP, Barton FB, Waclawiw M, Eckert SV. Charache S, et al. Among authors: moore rd. Control Clin Trials. 1995 Dec;16(6):432-46. doi: 10.1016/s0197-2456(95)00098-4. Control Clin Trials. 1995. PMID: 8925656 Free article. Clinical Trial.

2

Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.

Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G Jr, Platt OS, et al. Charache S, et al. Among authors: moore rd. Blood. 1992 May 15;79(10):2555-65. Blood. 1992. PMID: 1375104 Free article. Clinical Trial.

3

An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender, and age.

Chang YC, Smith KD, Moore RD, Serjeant GR, Dover GJ. Chang YC, et al. Among authors: moore rd. Blood. 1995 Feb 15;85(4):1111-7. Blood. 1995. PMID: 7531513 Free article.

4

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Charache S, et al. Among authors: moore rd. N Engl J Med. 1995 May 18;332(20):1317-22. doi: 10.1056/NEJM199505183322001. N Engl J Med. 1995. PMID: 7715639 Free article. Clinical Trial.

5

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP. Charache S, et al. Among authors: moore rd. Medicine (Baltimore). 1996 Nov;75(6):300-26. doi: 10.1097/00005792-199611000-00002. Medicine (Baltimore). 1996. PMID: 8982148 Free article. Clinical Trial.

6

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK. Moore RD, et al. Am J Hematol. 2000 May;64(1):26-31. doi: 10.1002/(sici)1096-8652(200005)64:1<26::aid-ajh5>3.0.co;2-f. Am J Hematol. 2000. PMID: 10815784 Free article. Clinical Trial.

7

Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients.

Moore RD, Lerner SA, Levine DP. Moore RD, et al. J Infect Dis. 1992 Apr;165(4):683-8. doi: 10.1093/infdis/165.4.683. J Infect Dis. 1992. PMID: 1552197 Clinical Trial.

8

Anemia and survival in HIV infection.

Moore RD, Keruly JC, Chaisson RE. Moore RD, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):29-33. doi: 10.1097/00042560-199809010-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9732065

9

Human immunodeficiency virus infection, anemia, and survival.

Moore RD. Moore RD. Clin Infect Dis. 1999 Jul;29(1):44-9. doi: 10.1086/520178. Clin Infect Dis. 1999. PMID: 10433563 Review.

10

Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.

Moore RD, Wong WM, Keruly JC, McArthur JC. Moore RD, et al. AIDS. 2000 Feb 18;14(3):273-8. doi: 10.1097/00002030-200002180-00009. AIDS. 2000. PMID: 10716503

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

905 results

Search Page